Please try another search
For the fiscal year ended 31 December 2016, Middle East Pharmactl&Chem Inds&Med PSC revenues decreased 62% to JD2.1M. Net loss decreased 8% to JD3.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Selling & Distribution Expenses decrease of 62% to JD1M (expense), Expired Goods increase from JD0K to JD629K (income).
Period Ending: | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 |
---|---|---|---|---|
Total Revenue | 0.23 | 0.73 | 0.72 | 0.39 |
Gross Profit | -0.37 | -0.1 | -0.13 | -0.27 |
Operating Income | -1.29 | 0.1 | -0.87 | -0.8 |
Net Income | -1.43 | -0.03 | -1.04 | -0.98 |
Period Ending: | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 |
---|---|---|---|---|
Total Assets | 16.6 | 16.88 | 17.88 | 19.62 |
Total Liabilities | 19.16 | 18.01 | 18.98 | 19.69 |
Total Equity | -2.57 | -1.13 | -1.1 | -0.06 |
Period Ending: | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 |
---|---|---|---|---|
Period Length: | 12 Months | 9 Months | 6 Months | 3 Months |
Cash From Operating Activities | -0.03 | 1.54 | 1.51 | 1.01 |
Cash From Investing Activities | -0.06 | -0.04 | -0.03 | -0.01 |
Cash From Financing Activities | 0.16 | -1.53 | -1.42 | -0.8 |
Net Change in Cash | 0.07 | -0.03 | 0.07 | 0.2 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review